U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. About FDA
  3. FDA Organization
  4. Office of the Commissioner
  5. Office of the Chief Scientist
  6. National Center for Toxicological Research
  7. Science & Research (NCTR)
  8. Xiaobo He
  1. Science & Research (NCTR)

Xiaobo He Ph.D.
Leadership Role

Visiting Scientist — Office of Scientific Coordination

NO PHOTO AVAILABLE


Xiaobo He, Ph.D.
(870) 543-7121
NCTRResearch@fda.hhs.gov  

Back to NCTR Principal Investigators page

About  |  Publications 

Background

Xiaobo He received his Ph.D. in microbial and biochemical pharmacy from the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College in Beijing, China in 2005. He received his degree with a specialization in the establishment and application of screening models for seeking inhibitors against matrix metalloproteinases and their use in suppressing tumor invasion and metastasis. Dr. He continued to conduct studies at the same institution from 2005 to 2014, focusing on the following three fields: 1) in vitro and in vivo evaluation of anticancer, anti-osteoporotic, and anti-atherosclerotic activities of synthetic compounds; 2) pharmacokinetic and toxicological testing of new drug candidates; 3) establishment and application of screening models for seeking BMP2 up-regulators from fermentation broths of streptomyces, identification and mechanism study of BMP2 up-regulators as potential anti-osteoporotic compounds.

In 2014, Dr. He participated in the Oak Ridge Institute for Science and Education (ORISE) Research Participation Program at the National Center for Toxicological Research (NCTR) as a postdoctoral fellow, where he studied the mechanism of tumorigenic activity of pyrrolizidine alkaloids (PAs) and how these data relate to risk assessment. From 2017 to 2018, Dr. He worked at the Center for Translational Biomedical Research at the University of North Carolina, where he worked on comprehensive profiling of non-enzymatically glycated (Amadori-modified) lipids in human plasma samples related to diabetic cardiovascular diseases. In 2018, Dr. He returned to NCTR in his current position in the Analytical Chemistry Group of the Office of Scientific Coordination, where he collaborates with scientists on toxicology or toxicokinetic studies by performing quantitative and qualitative analyses primarily using chromatography-hyphenated mass spectrometry techniques.

Research Interests

Dr. He collaborates with other NCTR scientists on projects funded by the Center for Tobacco Products, the National Toxicology Program, and FDA. His primary duty is to conduct mass spectral analyses of complex mixtures of interest to the FDA, such as natural products, trace metals, drugs, colors, and tobacco-related products. Dr. He’s main research interests include: 1) establishment and application of bioanalytical methodology for trace analysis of compounds and their metabolites in bio-samples using mass spectral approaches; 2) pharmacokinetic / pharmacodynamic modelling by in vivo and in vitro assays; and 3) application of metabolomic / proteomic / lipidomic techniques to toxicological studies.

Professional Societies/National and International Groups

Society of Toxicology
Member
2019

Selected Publications

Effects of Glutathione and Cysteine on Pyrrolizidine Alkaloid-induced Hepatotoxicity and DNA Adduct Formation in Rat Primary Hepatocytes.
He X., Xia Q., Shi Q., and Fu P.P. 
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2020, 38(2):109-123, doi: 10.1080/26896583.2020.1738161 [Epub 2020 Apr 27].

Quantitation of DNA Reactive Pyrrolic Metabolites of Senecionine – A Carcinogenic Pyrrolizidine Alkaloid by LC/MS/MS Analysis.
Xia Q., He X., Shi Q., Ge L., and Fu P.P. 
J Food Drug Anal. 2020, 28(1):167-174, doi: 10.1016/j.jfda.2019.12.001 [Epub 2019 Dec 13].

Comprehensive Identification of Amadori Compound-modified Phosphatidylethanolamines in Human Plasma.
He X., Chen G.Y., and Zhang Q.
Chem Res Toxicol. 2019,  32(7): 1449-1457, doi: 10.1021/acs.chemrestox.9b00158 [Epub 2019 Jun 26].

1-Formyl-7-hydroxy-6,7-dihydro-5H-pyrrolizine (1-CHO-DHP): A Potential Proximate Carcinogenic Metabolite of Pyrrolizidine Alkaloids.
He X., Xia Q., Costa G.G., Lin G., and Fu P.P. 
Chem Res Toxicol. 2019,  32(6): 1193-1203, doi: 10.1021/acs.chemrestox.9b00038 [Epub 2019 Jun 3].

Primary and Secondary Pyrrolic Metabolites of Pyrrolizidine Alkaloids Form DNA Adducts in Human A549 Cells.
He X., Xia Q., Wu Q., Tolleson W.H., Lin G., and Fu P.P. 
Toxicol In Vitro. 2019, February; 54(2): 286-294, doi: 10.1016/j.tiv.2018.10.009 [Epub 2018 Oct 24].

Synthesis, Purification and Mass Spectrometric Characterization of Stable Isotope-labeled Amadori-glycated Phospholipids.
He X. and Zhang Q. 
ACS Omega. 2018,  3(11): 15725-15733, doi: 10.1021/acsomega.8b01893 [Epub 2018 Nov 19]. 

Pyrrolizidine Alkaloid Secondary Pyrrolic Metabolites Construct Multiple Activation Pathways Leading to DNA Adduct Formation and Potential Liver Tumor Initiation.
Xia Q., He X., Ma L., Chen S., and Fu P.P. 
Chem Res Toxicol. 2018,  31(7): 619-628, doi: 10.1021/acs.chemrestox.8b00096 [Epub 2018 Jun 13].

Pyrrolizidine Alkaloid-derived DNA Adducts are Common Toxicological Biomarkers of Pyrrolizidine Alkaloid N-oxides.
He X., Xia Q., Woodling K., Lin G., and Fu P.P. 
J Food Drug Anal. 2017,  25(4): 984-991, doi: 10.1016/j.jfda.2017.09.001 [Epub 2017 Sep 19].

7-Glutathione-pyrrole and 7-cysteine-pyrrole are Potential Carcinogenic Metabolites of Pyrrolizidine Alkaloids.
He X., Xia Q., and Fu P.P. 
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2017,  35(2): 69-83, doi: 10.1080/10590501.2017.1298358 [Epub 2017 Mar 1].

Detection of Pyrrolizidine Alkaloid DNA Adducts in Livers of Cattle Poisoned with Heliotropium europaeum.
Fu P.P., Xia Q., He X., Barel S., Edery N., Beland F.A., and Shimshoni J.A. 
Chem Res Toxicol. 2017, 30(3): 851-858, doi: 10.1021/acs.chemrestox.6b00456 [Epub 2017 Feb 10].

7-Cysteine-pyrrole Conjugate: A New Potential DNA Reactive Metabolite of Pyrrolizidine Alkaloids.
He X., Xia Q., Ma L., and Fu P.P. 
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2016, 34(1): 57-76, doi: 10.1080/10590501.2015.1135593

7-N-Acetylcysteine-pyrrole Conjugate—A Potent DNA Reactive Metabolite of Pyrrolizidine Alkaloids.
He X., Ma L., Xia Q., and Fu P.P. 
J Food Drug Anal. 2016, 24(4): 682-694, doi: 10.1016/j.jfda.2016.08.001 [Epub 2016 Sep 10].

7-Glutathione Pyrrole Adduct: A Potential DNA Reactive Metabolite of Pyrrolizidine Alkaloids.
Xia Q., Ma L., He X., Cai L., and Fu PP. 
Chem Res Toxicol. 2015, 28(4): 615-620, doi: 10.1021/tx500417q [Epub 2015 Mar 31].

Contact Information
Xiaobo He
(870)543-7121
Expertise
Expertise
Approach
Domain
Technology & Discipline
Metabolomics
Proteomics
Toxicology
Back to Top